Tumor regression by targeted gene delivery to the neovasculature

被引:699
作者
Hood, JD
Bednarski, M
Frausto, R
Guccione, S
Reisfeld, RA
Xiang, R
Cheresh, DA
机构
[1] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[2] Stanford Sch Med, Lucas Magnet Resonance Spect Res Ctr, Stanford, CA 94305 USA
关键词
D O I
10.1126/science.1070200
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Efforts to influence the biology of blood vessels by gene delivery have been hampered by a lack of targeting vectors specific for endothelial cells in diseased tissues. Here we show that a cationic nanoparticle (NP) coupled to an integrin alphavbeta3-targeting ligand can deliver genes selectively to angiogenic blood vessels in tumor-bearing mice. The therapeutic efficacy of this approach was tested by generating NPs conjugated to a mutant Raf gene, ATP(mu)-Raf, which blocks endothelial signaling and angiogenesis in response to multiple growth factors. Systemic injection of the NP into mice resulted in apoptosis of the tumor-associated endothelium, ultimately leading to tumor cell apoptosis and sustained regression of established primary and metastatic tumors.
引用
收藏
页码:2404 / 2407
页数:4
相关论文
共 19 条
[1]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[2]   ANTIBODIES TO THE VITRONECTIN RECEPTOR (INTEGRIN ALPHA(V)BETA(3)) INHIBIT BINDING AND INFECTION OF FOOT-AND-MOUTH-DISEASE VIRUS TO CULTURED-CELLS [J].
BERINSTEIN, A ;
ROIVAINEN, M ;
HOVI, T ;
MASON, PW ;
BAXT, B .
JOURNAL OF VIROLOGY, 1995, 69 (04) :2664-2666
[3]   Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene [J].
Blezinger, P ;
Wang, JJ ;
Gondo, M ;
Quezada, A ;
Mehrens, D ;
French, M ;
Singhal, A ;
Sullivan, S ;
Rolland, A ;
Ralston, R ;
Min, W .
NATURE BIOTECHNOLOGY, 1999, 17 (04) :343-348
[4]   INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].
BROOKS, PC ;
MONTGOMERY, AMP ;
ROSENFELD, M ;
REISFELD, RA ;
HU, TH ;
KLIER, G ;
CHERESH, DA .
CELL, 1994, 79 (07) :1157-1164
[5]  
Carron CP, 1998, CANCER RES, V58, P1930
[6]   Nonpeptide αvβ3 antagonists.: 1.: Transformation of a potent, integrin-selective αIIbβ3 antagonist into a potent αvβ3 antagonist [J].
Duggan, ME ;
Duong, LT ;
Fisher, JE ;
Hamill, TG ;
Hoffman, WF ;
Huff, JR ;
Ihle, NC ;
Leu, CT ;
Nagy, RM ;
Perkins, JJ ;
Rodan, SB ;
Wesolowski, G ;
Whitman, DB ;
Zartman, AE ;
Rodan, GA ;
Hartman, GD .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) :3736-3745
[7]   Integrinαvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis [J].
Eliceiri, BP ;
Klemke, R ;
Strömblad, S ;
Cheresh, DA .
JOURNAL OF CELL BIOLOGY, 1998, 140 (05) :1255-1263
[8]   Adhesion events in angiogenesis [J].
Eliceiri, BP ;
Cheresh, DA .
CURRENT OPINION IN CELL BIOLOGY, 2001, 13 (05) :563-568
[9]   INVOLVEMENT OF INTEGRIN ALPHA-V GENE-EXPRESSION IN HUMAN-MELANOMA TUMORIGENICITY [J].
FELDINGHABERMANN, B ;
MUELLER, BM ;
ROMERDAHL, CA ;
CHERESH, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (06) :2018-2022
[10]   Integrin αvβ3 mediates rotavirus cell entry [J].
Guerrero, CA ;
Méndez, E ;
Zárate, S ;
Isa, P ;
López, S ;
Arias, CF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (26) :14644-14649